Preclinical Studies with Human Tumour Xenografts Using Rat Monoclonal Antibodies Directed Against the Epidermal Growth Factor Receptor
There is abundant evidence to suggest that over-expression of growth factor receptors and/or autocrine production of one or more ligands may provide tumour cells with significant advantages in growth and dissemination. One clinically important group is that of the c-erbB family of type 1 receptor tyrosine kinases exemplified by epidermal growth factor receptor (EGFR; reviewed by Harris et al. 1992; Khazaie et al. 1993; Modjtahedi and Dean 1994; Baselga and Mendelsohn 1994; Eccles et al. 1995). The cell surface location of these molecules renders them attractive targets for a variety of immunotherapeutic strategies, some of which are showing promise in preclinical and early clinical trials.
KeywordsEpidermal Growth Factor Receptor Athymic Mouse Human Tumour Xenograft A549 Lung Adenocarcinoma Cell Therapeutic Mabs
Unable to display preview. Download preview PDF.
- Eccles S, Modjtahedi H, Box G, Court W, Sandle J, Dean C (1995) Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy. Invasion Metastasis 14:337–348Google Scholar
- Modjtahedi H, Dean C (1994) The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (review). Int J Oncol 4:227–296Google Scholar
- Modjtahedi H, Styles J, Box G, Eccles S, Gusterson B, Dean C (1993b) Antitumour activity of rat Mabs to the human receptor for EGF. In: Epenetos AA, Lemoine NR (eds) Mutant oncogenes: targets for therapy? Chapman and Hall, London, p 35Google Scholar
- Modjtahedi H, Jackson E, Dean C (1995) Monovalent antibodies to the epidermal growth factor (EGF) receptor: effects on proliferation and differentiation of tumors overexpressing the EGF receptor. Tumor Target 1:99–106Google Scholar
- Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C, Gore M (1996) Phase 1 trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 73:228–235PubMedCrossRefGoogle Scholar